Kinaset Therapeutics was formed to develop novel therapeutics for severe respiratory diseases. Kinaset’s lead program KN-002 is a novel pan-JAK inhibitor for the treatment of eosinophilic and non-eosinophilic severe asthma.
| Headquarters | Medfield, MA |
| Website | kinasettherapeutics.com |
| Pipeline Status | Phase 1-ready |
| Partners | Vectura |
| @KinasetT | |
| Kinaset Therapeutics |